Related Experiment Videos
Gene transfer of beta-adrenergic signaling components for heart failure
1Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Insights
Heart failure involves changes in the beta-adrenergic receptor system. Targeting this system offers a promising therapeutic strategy for heart failure treatment, as shown in animal studies.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Biochemistry
Background:
- Heart failure is a major cause of death with limited prognostic improvements despite clinical advances.
- It is a common endpoint for diseases like hypertension, coronary artery disease, and cardiomyopathy.
- Biochemical changes in the failing heart muscle, particularly in beta-adrenergic receptor signaling, are key.
Purpose of the Study:
- To review biochemical alterations in heart failure.
- To discuss novel therapeutic strategies targeting the beta-adrenergic receptor system.
- To highlight findings from transgenic mouse and gene therapy studies.
Main Methods:
- Review of biochemical changes in heart failure.
- Analysis of studies using transgenic mice.
- Examination of beta-adrenergic receptor gene therapy in larger animals.
Main Results:
- Alterations in the beta-adrenergic receptor signaling system are common in heart failure.
- Transgenic and gene transfer techniques support the beta-adrenergic receptor system as a therapeutic target.
- Studies in mice and larger animals provide insights into novel treatment strategies.
Conclusions:
- The beta-adrenergic receptor system is a viable molecular target for heart failure therapy.
- Advances in gene transfer and transgenic models offer new therapeutic avenues.
- Further research in this area holds promise for improving heart failure prognosis.
Abstract:
Heart failure represents one of the leading causes for morbidity and mortality in this country. Despite advances in clinical management, no significant improvements in prognosis have been achieved. Heart failure itself represents a final common endpoint for several disease entities, including hypertension, coronary artery disease, and cardiomyopathy. However, certain biochemical features remain common to the failing myocardium. Foremost among these are alterations in the beta-adrenergic receptor signaling system including G protein and associated regulatory proteins. Recent advances in myocardial transgenic and gene transfer techniques have supported the hypothesis that, on a molecular level, the beta-adrenergic receptor system is a viable therapeutic target for the treatment of heart failure. In this review, we will discuss the biochemical changes that accompany heart failure as well as corresponding novel therapeutic strategies that were uncovered by studies in transgenic mice as well as with beta-adrenergic receptor based gene therapy studies in larger animals.